Eclectic Associates Inc. ADV Decreases Holdings in Danaher Co. (NYSE:DHR)

Eclectic Associates Inc. ADV cut its holdings in shares of Danaher Co. (NYSE:DHR) by 13.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 887 shares of the conglomerate’s stock after selling 139 shares during the quarter. Eclectic Associates Inc. ADV’s holdings in Danaher were worth $247,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in DHR. Tsfg LLC raised its stake in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher during the second quarter worth approximately $25,000. nVerses Capital LLC purchased a new position in shares of Danaher during the second quarter worth approximately $25,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher during the first quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. purchased a new position in shares of Danaher during the fourth quarter worth approximately $42,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on DHR shares. Leerink Partners lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a report on Friday, September 6th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Stephens initiated coverage on shares of Danaher in a report on Tuesday. They issued an “overweight” rating and a $315.00 price target on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Stock Down 0.2 %

Shares of DHR traded down $0.49 during trading hours on Friday, hitting $270.03. The company had a trading volume of 1,132,669 shares, compared to its average volume of 2,759,666. The firm has a fifty day moving average price of $271.07 and a 200-day moving average price of $258.56. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $200.01 billion, a price-to-earnings ratio of 45.77, a P/E/G ratio of 4.55 and a beta of 0.83. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm earned $2.05 EPS. Danaher’s revenue was down 2.9% on a year-over-year basis. On average, equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.